Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Antrafenine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 7/20 | 0.49 |
| ▸ | DRD3 | P35462 | 7/20 | 0.49 |
| ▸ | HTR2A | P28223 | 4/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MLNR | O43193 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Antrafenine SCHEMBL29623495 | 1.00 | HTR4 (0.51) | HTR4DRD2DRD3HTR2ASLC6A2 | |
| SCHEMBL11463910 | 0.92 | HTR4 (0.49) | HTR4DRD2DRD3HTR2ASLC6A2 | |
| Hydrochloric Acid SCHEMBL11463915 | 0.91 | HTR4 (0.48) | HTR4DRD2DRD3HTR2ASLC6A2 | |
| Florifenine SCHEMBL29400044 | 0.89 | SLC6A2 (0.49) | DRD2DRD3HTR2ASLC6A2PDE4D | |
| Florifenine SCHEMBL379372 | 0.89 | SLC6A2 (0.49) | DRD2DRD3HTR2ASLC6A2PDE4D | |
| SCHEMBL10510799 | 0.89 | RXFP1 (0.49) | DRD2DRD3HTR2ASLC6A2PDE4D | |
| SCHEMBL10631435 | 0.89 | RXFP1 (0.49) | DRD2DRD3HTR2ASLC6A2PDE4D | |
| SCHEMBL11471135 | 0.86 | HTR4 (0.50) | HTR4DRD2HTR2ASLC6A2PDE4D | |
| SCHEMBL10509149 | 0.85 | CYP1A2 (0.49) | DRD2DRD3HTR2ASLC6A2PDE4D | |
| SCHEMBL10626075 | 0.84 | CYP1A2 (0.48) | DRD2DRD3HTR2ASLC6A2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1806 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025213224-A1 | TREATMENT OF KCNT1-RELATED DISORDERS | UNIVERSITY OF SOUTH AUSTRALIA (AU) | 2025-10-16 | — | — | WO | claimed |
| WO-2025122021-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF), THROUGH TARGETING OF S100A9 AND CORRESPONDING DIMER PARTNER AND RECEPTORS | I3S - INSTITUTO DE INVESTIGAÇÃO E INOVAÇÃO EM SAÚDE, ASSOCIAÇÃO (PT) | 2025-06-12 | — | — | WO | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2025093735-A2 | AGENTS FOR USE IN THE TREATMENT OF TAUOPATHIES | DRUG TARGET IP B.V. (NL) | 2025-05-08 | — | — | WO | claimed |
| US-20240390406-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTIAGING DRUGS | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2024-11-28 | — | — | US | claimed |
| US-20240393332-A1 | MOLECULAR IDENTIFICATION OF COMPOUNDS TARGETING TRISTETRAPROLIN (TTP) AND TTP PHOSPHORYLATION | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2024-11-28 | — | — | US | claimed |
| EP-4467978-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTI-AGING DRUGS | King Faisal Specialist Hospital & Research Centre (SA) | 2024-11-27 | — | — | EP | claimed |
| EP-4467983-A1 | MOLECULAR IDENTIFICATION OF COMPOUNDS TARGETING TRISTETRAPROLIN (TTP) AND TTP PHOSPHORYLATION | King Faisal Specialist Hospital & Research Centre (SA) | 2024-11-27 | — | — | EP | claimed |
| US-20210379087-A1 | COMPOSITIONS FOR THE ELIMINATION OF SENESCENT CELLS | MEDIZINISCHE UNIVERSITÄT WIEN (AT) | 2021-12-09 | — | — | US | claimed |
| US-20200197377-A1 | METHODS FOR IMPROVING MEMORY AND COGNITION AND FOR TREATING MEMORY AND COGNITIVE DISORDERS | CAVION, INC. (US) | 2020-06-25 | — | — | US | claimed |
| EP-1429807-A2 | COMBINATION OF A NSAID AND A PDE-4 INHIBITOR | ALTANA Pharma AG (DE) | 2004-06-23 | — | — | EP | claimed |
| US-20030235617-A1 | Pharmaceutical dosage form for mucosal delivery | MCNEIL-PPC, INC | 2003-12-25 | — | — | US | claimed |
| US-20030180357-A1 | Pharmaceutical tablet | MCNEIL-PPC, INC | 2003-09-25 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| WO-2003066030-A2 | PHARMACEUTICAL TABLET | PHARMACIA CORPORATION (US) | 2003-08-14 | — | — | WO | claimed |
| WO-2003066029-A2 | PHARMACEUTICAL DOSAGE FORM FOR MUCOSAL DELIVERY | PHARMACIA CORPORATION (US) | 2003-08-14 | — | — | WO | claimed |
| WO-2003024489-A2 | COMBINATION OF A NSAID AND A PDE-4 INHIBITOR | ALTANA PHARMA AG (DE) | 2003-03-27 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030180357-A1 | Pharmaceutical tablet | GYPA, SORD, SRI | HTR4 1230/4885DRD2 793/4885DRD3 852/4885 |
| US-20200197377-A1 | METHODS FOR IMPROVING MEMORY AND COGNITION AND FOR TREATING MEMORY AND COGNITIVE DISORDERS | CACNA1G, CACNA1I, CACNA1H | HTR4 187/4885DRD2 324/4885DRD3 436/4885 |
| US-20030235617-A1 | Pharmaceutical dosage form for mucosal delivery | SI, UGGT1, GYPA | HTR4 1216/4885DRD2 1971/4885DRD3 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.